TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00025259

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bleomycin Sulfate
Description: Given IV or SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bleomycin Sulfate
Description: Given IV or SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bleomycin Sulfate
Description: Given IV or SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bleomycin Sulfate
Description: Given IV or SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bleomycin Sulfate
Description: Given IV or SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bleomycin Sulfate
Description: Given IV or SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bleomycin Sulfate
Description: Given IV or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study: NCT00025259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study: NCT02852785

Intervention type: BEHAVIORAL
Intervention: PNF D2 for flexion; low-to-moderate loading condition
Description: Exposure to upper extremity PNF D2 for flexion during low-to-moderate loading condition

Intervention type: BEHAVIORAL
Intervention: PNF D2 for flexion; moderate-to-high loading condition
Description: Exposure to upper extremity PNF D2 for flexion during moderate-to-high loading condition

Intervention type: BEHAVIORAL
Intervention: PNF D2 for flexion; moderate-to-high loading condition
Description: Exposure to upper extremity PNF D2 for flexion during moderate-to-high loading condition

Intervention type: BEHAVIORAL
Intervention: PNF D2 for flexion; moderate-to-high loading condition
Description: Exposure to upper extremity PNF D2 for flexion during moderate-to-high loading condition
Study: NCT00025259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study: NCT03087318

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Physical activity:~* 3 sessions / week at least~* at least during 30 minutes each session~* at least at 50% of the maximal heart rate measured during the exercise stress testing (from the screening)~* during 3 months.
Study: NCT02852785

Intervention type: BEHAVIORAL
Intervention: PNF D2 for flexion; moderate-to-high loading condition
Description: Exposure to upper extremity PNF D2 for flexion during moderate-to-high loading condition
Study: NCT00705406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peramivir
Description: 600 mg peramivir administered as bilateral 2-mL intramuscular injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (buffered diluent) administered as bilateral 2-mL intramuscular injection.
Study: NCT00025259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study: NCT03472352

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: An anticancer medication (A01) and immune cells (IC01)
Description: The administration of A01 and IC01 will be performed in the Second People's Hospital of Yibin, Sichuan, China. The subjects will be observed for any side effects during this time and all the adverse events will be recorded.
Study: NCT04031365

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Use of sterile, disposable needles in acupuncture

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: psychotherapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: psychotherapy
Study: NCT02966652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DITEST
Description: Lipid formulation of native oral testosterone.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DITEST
Description: Lipid formulation of native oral testosterone.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone undecanoate
Description: Generic treatment for patients with primary or secondary male hypogonadism
Study: NCT03844685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Promensil
Description: 1 tablet (80 mg) /day of MCE-11 (Promensil) taken orally for 24 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo tablet (80 mg) (without active principle) given once a day for 24 months
Study: NCT01584466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone
Description: The starting regimen will be a 'loading dose' strategy whereby the first injection will be 234 mg given on treatment week 0,day 1 and 156 mg (2nd injection) will be given 1 week later (days 5-9). Both are recommended to be administered in the deltoid muscle (PI 2011). Following the second dose, monthly maintenance doses will be administered in either the deltoid or gluteal muscle (PI 2011). The monthly (± 7 days) maintenance dose will be 117 mg.~Discontinuation of oral antipsychotics is recommended after the subjects receive paliperidone palmitate injection on Week 0/day 1. Continued oral antipsychotics may be used only if necessary.
Study: NCT03213028

Intervention type: OTHER
Group type: OTHER
Intervention: WHO Decision-Making Tool for Family Planning Clients and Providers
Description: Contraception decision-making tool
Study: NCT02434276

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAX2012Q
Description: Recombinant influenza hemagglutinin (HA) vaccine consisting of two influenza A subtypes and two influenza B lineages

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAX2012Q
Description: Recombinant influenza hemagglutinin (HA) vaccine consisting of two influenza A subtypes and two influenza B lineages

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone Quadrivalent
Description: Fluzone Quadrivalent (Influenza Vaccine)
Study: NCT00442104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganaxolone
Study: NCT01883193

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Comprehensive Maternal Nutrition Intervention
Description: The nutrition intervention will be delivered before conception or at 12 weeks gestation and continued through delivery and compared with a control group. The supplement to be used is a multi-micronutrient (MMN) fortified lipid-based supplement composed of dried skimmed milk, soybean and peanut extract, sugar, maltodextrin stabilizers, and emulsifiers.
Study: NCT02852785

Intervention type: BEHAVIORAL
Intervention: PNF D2 for flexion; moderate-to-high loading condition
Description: Exposure to upper extremity PNF D2 for flexion during moderate-to-high loading condition

Intervention type: BEHAVIORAL
Intervention: PNF D2 for extension; low-to-moderate loading condition
Description: Exposure to upper extremity PNF D2 for extension during low-to-moderate loading condition
Study: NCT04239768

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MonoDermà HA gel combined to a low level laser
Description: Two intradermal injections of the filler were performed during the basal and after 1 month, on the middle and inferior third of the face (1ml for each face side) using a needle (30G).~Immediately after both injection procedures, LLLT session were performed on the same face area for a total of 8 minutes, using three different wavelengths (450 nm, 650 nm and 1064 nm) simultaneously.
Study: NCT02852785

Intervention type: BEHAVIORAL
Intervention: PNF D2 for extension; low-to-moderate loading condition
Description: Exposure to upper extremity PNF D2 for extension during low-to-moderate loading condition

Intervention type: BEHAVIORAL
Intervention: PNF D2 for extension; low-to-moderate loading condition
Description: Exposure to upper extremity PNF D2 for extension during low-to-moderate loading condition

Intervention type: BEHAVIORAL
Intervention: PNF D2 for extension; low-to-moderate loading condition
Description: Exposure to upper extremity PNF D2 for extension during low-to-moderate loading condition

Intervention type: BEHAVIORAL
Intervention: PNF D2 for extension; low-to-moderate loading condition
Description: Exposure to upper extremity PNF D2 for extension during low-to-moderate loading condition

Intervention type: BEHAVIORAL
Intervention: PNF D2 for extension; moderate-to-high loading condition
Description: Exposure to upper extremity PNF D2 for extension during moderate-to-high loading condition

Intervention type: BEHAVIORAL
Intervention: PNF D2 for extension; moderate-to-high loading condition
Description: Exposure to upper extremity PNF D2 for extension during moderate-to-high loading condition

Intervention type: BEHAVIORAL
Intervention: PNF D2 for extension; moderate-to-high loading condition
Description: Exposure to upper extremity PNF D2 for extension during moderate-to-high loading condition

Intervention type: BEHAVIORAL
Intervention: PNF D2 for extension; moderate-to-high loading condition
Description: Exposure to upper extremity PNF D2 for extension during moderate-to-high loading condition

Intervention type: BEHAVIORAL
Intervention: PNF D2 for extension; moderate-to-high loading condition
Description: Exposure to upper extremity PNF D2 for extension during moderate-to-high loading condition
Study: NCT01185132

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: accelerated partial breast irradiation - 3D-conformal planning
Description: 38.5 Gy, 10 fractions over 5 days

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: accelerated partial breast irradiation - IMRT planning
Description: 38.5 Gy, 10 fractions over 5 days
Study: NCT01689714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tc 99m EC20
Study: NCT00305032

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: gastric balloon insertion
Description: patient would be offered endoscopic gastric balloon insertion
Study: NCT00951080

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional NPWT System
Description: Standard wound dressing applications followed by negative pressure system application per manufacturer recommendations.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SNaP Wound Care System
Description: Wound dressing applications using customized system. Dressing applications changes per manufacturer recommendation.
Study: NCT04562402

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phacoemulsification
Description: cataract surgery via phacoemulsification

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phacoemulsification
Description: cataract surgery via phacoemulsification

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic cyclophotocoagulation
Description: Endoscopic ablation of the ciliary body
Study: NCT01960998

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Muscle Training
Description: Evidence-based pelvic floor muscle training program that has been adapted to telehealth format. Training is begun 2-4 weeks before surgery and continued 2 months after surgery. Content is accessed in daily 10-minute sessions on a secure website

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perioperative Care and Wetness Management
Description: Telehealth program that includes include general perioperative care; wetness, odor and skin care management; and outcome measures. The program is begun 1-4 weeks before surgery and continued 2 months after surgery. Content is accessed in 10-minute sessions on a secure website - daily preoperatively and for the first 2 months post-operatively, then weekly until 6 months post-operatively.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Perioperative Care and Wetness Management
Description: Telehealth program that includes include general perioperative care; wetness, odor and skin care management; and outcome measures. The program is begun 1-4 weeks before surgery and continued 2 months after surgery. Content is accessed in 10-minute sessions on a secure website - daily preoperatively and for the first 2 months post-operatively, then weekly until 6 months post-operatively.
Study: NCT00790166

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP + ThermoSmart™ humidity
Description: an absolute humidity (AH) of 28 mg/l +/- 2mg/l

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP + Conventional humidity
Description: an absolute humidity (AH) of 18 mg/l +/- 2 mg/l

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP + No added humidity
Description: ambient humidity
Study: NCT00759356

Intervention type: DRUG
Group type: OTHER
Intervention: morphine sulfate sustained-release capsules
Description: 1 x 200 mg, single-dose capsule

Intervention type: DRUG
Group type: OTHER
Intervention: morphine sulfate sustained-release capsules
Description: 1 x 200 mg, single-dose capsule

Intervention type: DRUG
Group type: OTHER
Intervention: KADIAN
Description: 2 x 100 mg, single-dose capsule

Intervention type: DRUG
Group type: OTHER
Intervention: KADIAN
Description: 2 x 100 mg, single-dose capsule
Study: NCT00704483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBR759
Description: Starting dose of 1g or 1.5g tid, with an increase of 1g tid every 2 weeks until serum phosphate level fall below target.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer HCl
Description: 0.8 g tid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBR759
Description: 1.5 g tid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer HCl
Description: 1.6 g tid
Study: NCT03199053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets, Oral, 5mg , Once daily Tablets, Oral, 10mg, Once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets, Oral, 5mg , Once daily Tablets, Oral, 10mg, Once daily
Study: NCT02417701

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapanisertib
Description: Given PO
Study: NCT02638727

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-Citrulline
Description: This group treat with L-Citrulline (3 grams per day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: This group treat with placebo dayley
Study: NCT01090960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0068
Description: Oral repeating dose
Study: NCT01636804

Intervention type: DEVICE
Intervention: Quicksite
Description: St. Jude Medical produced lead called Quicksite

Intervention type: DEVICE
Intervention: Quickflex
Description: St. Jude Medical produced lead called Quickflex
Study: NCT03107754

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine
Description: Paracervical block will be injected at 2 points at the cervicovaginal junction to decrease pain

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine-Sodium Bicarbonate
Description: Paracervical block will be injected at 2 points at the cervicovaginal junction to decrease pain
Study: NCT03498300

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tdap vaccine
Description: A single dose of Tdap vaccine at GA 27 - 36 weeks
Study: NCT02563353

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole-body vibration
Description: Whole-body vibration on vibration platforms. 30-40 Hertz, from 2 mm (low) to 4 mm (high) amplitude,~1 minutes x 6 with 1 minute break between. 3 times a week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole-body vibration
Description: Whole-body vibration on vibration platforms. 30-40 Hertz, from 2 mm (low) to 4 mm (high) amplitude,~1 minutes x 6 with 1 minute break between. 3 times a week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: teriparatide
Description: Teriparatide, 20 microgram/day. 24 months of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teriparatide
Description: Teriparatide, 20 microgram/day. 24 months of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teriparatide
Description: Teriparatide, 20 microgram/day. 24 months of treatment.
Study: NCT03199053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Tablets, Oral, 2.5mg Once daily Tablets, Oral, 5mg, Once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Tablets, Oral, 2.5mg Once daily Tablets, Oral, 5mg, Once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to dapagliflozin 5mg and 10 mg/saxagliptin 2.5 mg and 5 mg, Tablets, oral, Once daily
Study: NCT02899234

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: E-cigarette
Description: A third generation e-cigarette device will be used with pre-determined temperature, voltage and wattage settings.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: E-cigarette
Description: A third generation e-cigarette device will be used with pre-determined temperature, voltage and wattage settings.
Study: NCT03027778

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Intradialytic pedalling exercise during regular dialysis sessions (3x per week) for 4 months
Study: NCT01593215

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Yohimbine
Description: Yohimbine capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Yohimbine
Description: Yohimbine capsule
Study: NCT02590848

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Walnut intake
Description: Nutritional intervention: 30g walnut kernels per day
Study: NCT01867268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: Acetazolamide administration for 10 days adjust dosage with weight of the patient
Study: NCT02463747

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin/tazobactam
Description: Initial treatment will be with Piperacillin + Tazobactam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam
Description: Initial treatment will be with Piperacillin + Tazobactam

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftazidim
Description: Patient with sensitivity to penicillin will receive Ceftazidim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftazidim
Description: Patient with sensitivity to penicillin will receive Ceftazidim

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: In cases of hypotension that do not respond to fluids resuscitation , and in consultation with the infectious diseases unit - we will start empirical treatment with Meropenem

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem
Description: In cases of hypotension that do not respond to fluids resuscitation , and in consultation with the infectious diseases unit - we will start empirical treatment with Meropenem

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Supplementation of Vancomycin will be at the discretion of the treating physician

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Supplementation of Vancomycin will be at the discretion of the treating physician
Study: NCT01743235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Solid Oral Dosage. Maximum every other day (on an as needed basis)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Solid Oral Dosage. Maximum every other day (on an as needed basis)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Solid Oral Dosage. Maximum every other day (on an as needed basis)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Solid Oral Dosage. Maximum every other day (on an as needed basis)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Solid Oral Dosage. Maximum every other day (on an as needed basis)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Solid Oral Dosage. Maximum every other day (on an as needed basis)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone hydrochloride
Description: Solid Oral Dosage. Maximum every other day (on an as needed basis)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone hydrochloride
Description: Solid Oral Dosage. Maximum every other day (on an as needed basis)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone hydrochloride
Description: Solid Oral Dosage. Maximum every other day (on an as needed basis)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone hydrochloride
Description: Solid Oral Dosage. Maximum every other day (on an as needed basis)
Study: NCT01867268

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: prone positioning
Description: prone positioning the patient for 10 days following the surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acetazolamide+ prone positioning
Description: administration of acetazolamide and position the patient for 10 days following the surgery
Study: NCT03697629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Patients will receive daratumumab, in the following schedule:~Daratumumab 8mg/kg in 500 mL over 4 hours Cycle 1 Day 1, Daratumumab 16mg/kg in 500 mL over 90 minutes (20% of dose given in first 30 minutes and remaining 80% of dose given over 60 minutes) Cycle 1 Days 8, 15 and 22; Cycle 2 Days 1, 8, 15, and 22, and on Days 1 and 15 for Cycles 3-6.
Study: NCT02921854

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood withdrawal
Description: For each patient, 3 blood withdrawals of 25 ml each will take place during treatment